Pain psychiatry and somatic symptom disorders — structured clinical viva · Psych Vivas

Prompt

You are the C-L psychiatry registrar. A pain clinic asks for review of a 52-year-old man with chronic widespread pain, high health anxiety, PHQ-15 high, depression, and escalating oxycodone plus night diazepam. Physicians want 'a somatisation label so we can stop investigating' and pharmacy wants opioid weaning. Discuss nosology (SSD vs IAD vs ICD-11), assessment, differentials, CBT evidence, medication options with doses, and dual diagnosis.

Interpretation

Reveal interpretation

Reject “label to stop thinking.” SSD is a positive diagnosis of disproportionate response to symptoms, not a licence to ignore red flags forever.[1]

Nosology. SSD vs IAD (symptom load); map hypochondriasis legacy; mention ICD-11 bodily distress / hypochondriasis framing briefly.[1]

Assessment. Alliance; PHQ-15; depression/suicide; opioid/benzo map and OUD criteria; functional goals; shared re-investigation thresholds.[7]

Treatment. CBT for health anxiety (Barsky, Tyrer CHAMP); pain psychology; duloxetine titration spine 30→60 mg when indicated; TCA low-dose night caution; deprescribe high-risk sedative–opioid combinations carefully.[2][3][5]

Opioids. SPACE: opioids not superior for function in studied chronic pain; CDC 2022 principles; dual diagnosis if OUD present.[4][6][7]

Escalating questions (model points)

Expect: DSM-5 SSD no longer requires unexplained symptoms; IAD has care-seeking vs care-avoidant forms; PHQ-15 rates somatic severity; name at least one CBT health-anxiety trial; state SPACE primary message; give duloxetine or amitriptyline practical start dose with cautions; describe OUD dual-diagnosis approach without stigma; refuse factitious/malingering labels without evidence.[1][2][4][5]

Key points

References

[1]Dimsdale JE, Creed F, Escobar J, et al. Somatic symptom disorder: an important change in DSM J Psychosom Res, 2013.PMID 23972410
[2]Tyrer P, Cooper S, Salkovskis P, et al. Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial Lancet, 2014.PMID 24139977
[3]Barsky AJ, Ahern DK Cognitive behavior therapy for hypochondriasis: a randomized controlled trial JAMA, 2004.PMID 15039413
[4]Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial JAMA, 2018.PMID 29509867
[5]Lunn MP, Hughes RA, Wiffen PJ Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia Cochrane Database Syst Rev, 2014.PMID 24385423
[6]Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 MMWR Recomm Rep, 2022.PMID 36327391
[7]Howe CQ, Sullivan MD The missing 'P' in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care Gen Hosp Psychiatry, 2014.PMID 24211157

Interpretation

Reveal interpretation

Reject “label to stop thinking.” SSD is a positive diagnosis of disproportionate response to symptoms, not a licence to ignore red flags forever.[1]

Nosology. SSD vs IAD (symptom load); map hypochondriasis legacy; mention ICD-11 bodily distress / hypochondriasis framing briefly.[1]

Assessment. Alliance; PHQ-15; depression/suicide; opioid/benzo map and OUD criteria; functional goals; shared re-investigation thresholds.[7]

Opioids. SPACE: opioids not superior for function in studied chronic pain; CDC 2022 principles; dual diagnosis if OUD present.[4][6][7]

Escalating questions (model points)

Key points

References

[1]Dimsdale JE, Creed F, Escobar J, et al. Somatic symptom disorder: an important change in DSM J Psychosom Res, 2013.PMID 23972410
[2]Tyrer P, Cooper S, Salkovskis P, et al. Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial Lancet, 2014.PMID 24139977
[3]Barsky AJ, Ahern DK Cognitive behavior therapy for hypochondriasis: a randomized controlled trial JAMA, 2004.PMID 15039413
[4]Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial JAMA, 2018.PMID 29509867
[5]Lunn MP, Hughes RA, Wiffen PJ Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia Cochrane Database Syst Rev, 2014.PMID 24385423
[6]Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 MMWR Recomm Rep, 2022.PMID 36327391
[7]Howe CQ, Sullivan MD The missing 'P' in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care Gen Hosp Psychiatry, 2014.PMID 24211157